Tirzepatide vs PT-141
A comprehensive, data-driven comparison of Tirzepatide (Mounjaro) and PT-141 (Bremelanotide). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tirzepatide Mounjaro, Zepbound | PT-141 Bremelanotide, Vyleesi |
|---|---|---|
| FDA Status | FDA Approved | FDA Approved |
| Category | Weight Loss | Sexual Health |
| Primary Use | Type 2 diabetes, chronic weight management, and obstructive sleep apnea | Hypoactive sexual desire disorder (HSDD) in women |
| Weight Loss % | 22.5% | N/A |
| Monthly Cost | $1,100 - $1,100/mo | $800 - $1,200/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 15mg weekly (max dose) | 1.75mg as needed, at least 45 min before activity |
| Frequency | Weekly | As needed |
| Mechanism | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Approved | Approved |
Key Differences
- 1Tirzepatide has clinical weight loss data (22.5%), while PT-141 is not primarily indicated for weight loss.
- 2PT-141 is generally more affordable ($800 - $1,200/mo) compared to Tirzepatide ($1,100 - $1,100/mo).
- 3Tirzepatide is dosed weekly, while PT-141 is as needed.
- 4They belong to different categories: Tirzepatide (Weight Loss) vs PT-141 (Sexual Health).
Which Is Better For...
PT-141
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
PT-141
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tirzepatide | $1,100 - $1,100/mo | FDA Approved | Eli Lilly |
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. They differ in FDA approval status, efficacy data, and cost.
Tirzepatide has demonstrated 22.5% average weight loss in clinical trials. PT-141 is not primarily used for weight loss.
Tirzepatide typically costs $1,100 - $1,100/mo, while PT-141 costs $800 - $1,200/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tirzepatide is FDA-approved. PT-141 is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. In December 2024, Zepbound became the first and only medication approved fo...
View Full Tirzepatide GuidePT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tirzepatide and PT-141 should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.